Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Lexicon Pharmaceuticals progresses in sotagliflozin and LX9211 programs

Lexicon Pharmaceuticals is making strides in its sotagliflozin and LX9211 programs, with a focus on commercial launch preparations and potential market impact. The company faces challenges in addressing inquiries from analysts and concerns about market receptivity. However, it remains confident in the potential of its compounds and looks forward to advancing into late-stage development and potential partnerships.

Lexicon Pharmaceuticals reports strong Q2 performance with FDA approval

Lexicon Pharmaceuticals showcased strong financial performance, driven by the FDA approval and market launch of INPEFA. While the company faces challenges related to the INPEFA launch, it also has opportunities to capitalize on the approval and drive further growth. Overall, the company's focus on advancing its product pipeline and maintaining a strong cash position positions it for future success.

Lexicon Pharmaceuticals reports progress and challenges in INPEFA launch

Lexicon Pharmaceuticals' Q3 earnings call highlighted the progress and challenges in the INPEFA launch, along with a strong focus on demand generation and formulary access. The company's strong cash position and upcoming milestones for its products indicate a positive outlook. However, concerns and uncertainties were raised regarding market access, sales focus, and partnership plans.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.

What's Next for Lexicon Pharmaceuticals?

Finally, shares of Lexicon Pharmaceuticals plunged 22%.

Why Lexicon Pharmaceuticals Slumped Today

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

News for Lexicon Pharmaceuticals Stock (LXRX)